A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors

Cell Reports

Volumn 15, Issue 11, 2016, Pages 2348-2356

  Gayvert, Kaitlyn M ^a,b   Dardenne, Etienne ^a   Cheung, Cynthia ^a   Boland, Mary Regina ^c   Lorberbaum, Tal ^c   Wanjala, Jackline ^d   Chen, Yu ^d   Rubin, Mark A ^a   Tatonetti, Nicholas P ^c   Rickman, David S ^a   Elemento, Olivier ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Tri Institutional Training Program in Computational Biology and Medicine   (United States)

^c Columbia University ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MYC PROTEIN; PREDNISONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; ESTROGEN RECEPTOR; MOLECULAR LIBRARY; TRIAZOLE DERIVATIVE;

ARTICLE; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG REPOSITIONING; DRUG TARGETING; HUMAN; HUMAN CELL; MEDICAL RECORD REVIEW; MIGRATION INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SYSTEMS BIOLOGY; ANTAGONISTS AND INHIBITORS; COMPUTER SIMULATION; ELECTRONIC HEALTH RECORD; KAPLAN MEIER METHOD; METABOLISM; MOLECULAR LIBRARY; ONCOGENE; PHARMACOLOGY; PROCEDURES; TUMOR CELL LINE;

AZEPINES; CELL LINE, TUMOR; COMPUTER SIMULATION; DEXAMETHASONE; DRUG REPOSITIONING; ELECTRONIC HEALTH RECORDS; HUMANS; KAPLAN-MEIER ESTIMATE; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84974715573     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.037     Document Type: Article

References (23)

1. Ablain J., Nasr R., Bazarbachi A., de Thé H. The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells?. Cancer Discov. 2011, 1:117-127.
2. Aksoy B.A., Gao J., Dresdner G., Wang W., Root A., Jing X., Cerami E., Sander C. PiHelper: an open source framework for drug-target and antibody-target data. Bioinformatics 2013, 29:2071-2072.
3. Chen D.W., Saha V., Liu J.Z., Schwartz J.M., Krstic-Demonacos M. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene 2013, 32:3039-3048.
4. Conde R., Belak Z.R., Nair M., O'Carroll R.F., Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem. Cell Biol. 2009, 87:845-851.
5. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
6. Das J., Yu H. HINT: High-quality protein interactomes and their applications in understanding human disease. BMC Syst. Biol. 2012, 6:92.
7. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
8. Elemento O., Rubin M.A., Rickman D.S. Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer. Cell Cycle 2012, 11:3380-3383.
9. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 2011, 9:e1001046. ENCODE Project Consortium.
10. Gobbi A., Iorio F., Dawson K.J., Wedge D.C., Tamborero D., Alexandrov L.B., Lopez-Bigas N., Garnett M.J., Jurman G., Saez-Rodriguez J. Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics 2014, 30:i617-i623.
11. Khurana E., Fu Y., Chen J., Gerstein M. Interpretation of genomic variants using a unified biological network approach. PLoS Comput. Biol. 2013, 9:e1002886.
12. Kittler R., Zhou J., Hua S., Ma L., Liu Y., Pendleton E., Cheng C., Gerstein M., White K.P. A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 2013, 3:538-551.
13. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., Pon A., Banco K., Mak C., Neveu V., et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011, 39:D1035-D1041.
14. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
15. Libermann T.A., Zerbini L.F. Targeting transcription factors for cancer gene therapy. Curr. Gene Ther. 2006, 6:17-33.
16. Mees C., Nemunaitis J., Senzer N. Transcription factors: their potential as targets for an individualized therapeutic approach to cancer. Cancer Gene Ther. 2009, 16:103-112.
17. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
18. Reinhold W.C., Sunshine M., Liu H., Varma S., Kohn K.W., Morris J., Doroshow J., Pommier Y. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012, 72:3499-3511.
19. Rickman D.S., Chen Y.B., Banerjee S., Pan Y., Yu J., Vuong T., Perner S., Lafargue C.J., Mertz K.D., Setlur S.R., et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010, 12:1031-1040.
20. Rickman D.S., Soong T.D., Moss B., Mosquera J.M., Dlabal J., Terry S., MacDonald T.Y., Tripodi J., Bunting K., Najfeld V., et al. Oncogene-mediated alterations in chromatin conformation. Proc. Natl. Acad. Sci. USA 2012, 109:9083-9088.
21. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
22. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
23. Xie L., Gazin C., Park S.M., Zhu L.J., Debily M.A., Kittler E.L., Zapp M.L., Lapointe D., Gobeil S., Virbasius C.M., Green M.R. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet. 2012, 8:e1003151.